vs
FIRST ADVANTAGE CORP（FA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是FIRST ADVANTAGE CORP的1.8倍（$772.1M vs $420.0M），Revvity净利率更高（12.7% vs 0.8%，领先11.9%），FIRST ADVANTAGE CORP同比增速更快（36.8% vs 5.9%），Revvity自由现金流更多（$161.8M vs $62.2M），过去两年FIRST ADVANTAGE CORP的营收复合增速更高（57.5% vs 9.0%）
First Advantage是全球领先的劳动力筛查与背景验证服务提供商，服务覆盖科技、医疗、金融、零售、制造等多个行业的各规模客户，助力企业管控雇佣风险、满足合规要求，打造安全可信的工作环境。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FA vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$420.0M
营收增速更快
FA
高出30.9%
5.9%
净利率更高
RVTY
高出11.9%
0.8%
自由现金流更多
RVTY
多$99.6M
$62.2M
两年增速更快
FA
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $420.0M | $772.1M |
| 净利润 | $3.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 10.7% | 14.5% |
| 净利率 | 0.8% | 12.7% |
| 营收同比 | 36.8% | 5.9% |
| 净利润同比 | 103.5% | 3.9% |
| 每股收益（稀释后） | $0.03 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FARVTY
| Q4 25 | $420.0M | $772.1M | ||
| Q3 25 | $409.2M | $698.9M | ||
| Q2 25 | $390.6M | $720.3M | ||
| Q1 25 | $354.6M | $664.8M | ||
| Q4 24 | $307.1M | $729.4M | ||
| Q3 24 | $199.1M | $684.0M | ||
| Q2 24 | $184.5M | $691.7M | ||
| Q1 24 | $169.4M | $649.9M |
净利润FARVTY
| Q4 25 | $3.5M | $98.4M | ||
| Q3 25 | $2.6M | $46.7M | ||
| Q2 25 | $308.0K | $53.9M | ||
| Q1 25 | $-41.2M | $42.2M | ||
| Q4 24 | $-100.4M | $94.6M | ||
| Q3 24 | $-8.9M | $94.4M | ||
| Q2 24 | $1.9M | $55.4M | ||
| Q1 24 | $-2.9M | $26.0M |
毛利率FARVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FARVTY
| Q4 25 | 10.7% | 14.5% | ||
| Q3 25 | 10.3% | 11.7% | ||
| Q2 25 | 9.7% | 12.6% | ||
| Q1 25 | 2.1% | 10.9% | ||
| Q4 24 | -26.3% | 16.3% | ||
| Q3 24 | 4.6% | 14.3% | ||
| Q2 24 | 5.4% | 12.4% | ||
| Q1 24 | -0.4% | 6.8% |
净利率FARVTY
| Q4 25 | 0.8% | 12.7% | ||
| Q3 25 | 0.6% | 6.7% | ||
| Q2 25 | 0.1% | 7.5% | ||
| Q1 25 | -11.6% | 6.4% | ||
| Q4 24 | -32.7% | 13.0% | ||
| Q3 24 | -4.4% | 13.8% | ||
| Q2 24 | 1.0% | 8.0% | ||
| Q1 24 | -1.7% | 4.0% |
每股收益（稀释后）FARVTY
| Q4 25 | $0.03 | $0.86 | ||
| Q3 25 | $0.01 | $0.40 | ||
| Q2 25 | $0.00 | $0.46 | ||
| Q1 25 | $-0.24 | $0.35 | ||
| Q4 24 | $-0.67 | $0.77 | ||
| Q3 24 | $-0.06 | $0.77 | ||
| Q2 24 | $0.01 | $0.45 | ||
| Q1 24 | $-0.02 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $240.0M | $919.9M |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $3.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.61× | — |
8季度趋势，按日历期对齐
现金及短期投资FARVTY
| Q4 25 | $240.0M | $919.9M | ||
| Q3 25 | $216.8M | $931.4M | ||
| Q2 25 | $184.3M | $991.8M | ||
| Q1 25 | $172.0M | $1.1B | ||
| Q4 24 | $168.7M | $1.2B | ||
| Q3 24 | $307.4M | $1.2B | ||
| Q2 24 | $269.6M | $2.0B | ||
| Q1 24 | $246.0M | $1.7B |
总债务FARVTY
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FARVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $920.7M | $7.9B | ||
| Q2 24 | $913.3M | $7.9B | ||
| Q1 24 | $907.7M | $7.8B |
总资产FARVTY
| Q4 25 | $3.8B | $12.2B | ||
| Q3 25 | $3.9B | $12.1B | ||
| Q2 25 | $3.9B | $12.4B | ||
| Q1 25 | $3.9B | $12.4B | ||
| Q4 24 | $3.9B | $12.4B | ||
| Q3 24 | $1.7B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.6B | $13.4B |
负债/权益比FARVTY
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.64× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 1.66× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $65.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $62.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 14.8% | 21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 19.01× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $188.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FARVTY
| Q4 25 | $65.9M | $182.0M | ||
| Q3 25 | $72.4M | $138.5M | ||
| Q2 25 | $37.3M | $134.3M | ||
| Q1 25 | $19.5M | $128.2M | ||
| Q4 24 | $-85.7M | $174.2M | ||
| Q3 24 | $43.5M | $147.9M | ||
| Q2 24 | $32.0M | $158.6M | ||
| Q1 24 | $38.3M | $147.6M |
自由现金流FARVTY
| Q4 25 | $62.2M | $161.8M | ||
| Q3 25 | $71.2M | $120.0M | ||
| Q2 25 | $36.1M | $115.5M | ||
| Q1 25 | $19.0M | $112.2M | ||
| Q4 24 | $-86.0M | $149.8M | ||
| Q3 24 | $43.1M | $125.6M | ||
| Q2 24 | $31.4M | $136.6M | ||
| Q1 24 | $38.0M | $129.7M |
自由现金流率FARVTY
| Q4 25 | 14.8% | 21.0% | ||
| Q3 25 | 17.4% | 17.2% | ||
| Q2 25 | 9.2% | 16.0% | ||
| Q1 25 | 5.4% | 16.9% | ||
| Q4 24 | -28.0% | 20.5% | ||
| Q3 24 | 21.6% | 18.4% | ||
| Q2 24 | 17.0% | 19.7% | ||
| Q1 24 | 22.4% | 20.0% |
资本支出强度FARVTY
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 0.1% | 3.4% | ||
| Q3 24 | 0.2% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.2% | 2.7% |
现金转化率FARVTY
| Q4 25 | 19.01× | 1.85× | ||
| Q3 25 | 27.91× | 2.97× | ||
| Q2 25 | 121.25× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 17.22× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FA
| First Advantage Americas | $209.9M | 50% |
| Sterling | $185.9M | 44% |
| First Advantage International | $24.2M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
